Cargando…

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation

Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion. Rifampin is a commonly used antibiotic for prosthetic joint infections (PJI) and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Rui-juan, Ling, Tao, Tang, Hong, Ge, Wei-hong, Jiang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342882/ https://www.ncbi.nlm.nih.gov/pubmed/34366862 http://dx.doi.org/10.3389/fphar.2021.706781

Ejemplares similares

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
por: Gerner, Bettina, et al.
Publicado: (2021)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

395. Safety and Tolerability of Rifampin in Staphylococcal Orthopedic Infections
por: Miller, Andy O, et al.
Publicado: (2019)

Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine
por: Ngo, Lien Thi, et al.
Publicado: (2022)

First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model
por: Chen, Jinliang, et al.
Publicado: (2022)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Physiologic and pharmacokinetic changes in pregnancy
por: Costantine, Maged M.
Publicado: (2014)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
por: Liu, Xiao-Qin, et al.
Publicado: (2022)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling
por: Hügl, Burkhard, et al.
Publicado: (2023)

New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
por: Borris, Lars Carl
Publicado: (2008)

Unraveling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
por: Yang, Xiaoxia, et al.
Publicado: (2015)

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction
por: Yamazaki, Shinji, et al.
Publicado: (2019)

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes
por: Benson, Eric A., et al.
Publicado: (2016)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
por: Wang, Xu, et al.
Publicado: (2022)

MEGen: A Physiologically Based Pharmacokinetic Model Generator
por: Loizou, George, et al.
Publicado: (2011)

The effect of ulinastatin on hemostasis in major orthopedic surgery
por: Lee, Jin Young, et al.
Publicado: (2010)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
por: Liu, Hongrui, et al.
Publicado: (2022)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium
por: Li, Xue, et al.
Publicado: (2022)

Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
por: Willmann, Stefan, et al.
Publicado: (2021)

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
por: Willmann, Stefan, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection
por: Guan, Xiao-duo, et al.
Publicado: (2021)

Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil
por: Shen, Chaozhuang, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
por: Yu, Zhiheng, et al.
Publicado: (2022)

Editorial: Pharmacokinetics of herbal medicines and herb-drug interactions
por: Jia, Wei-Wei, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine
por: Zheng, Liang, et al.
Publicado: (2022)

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
por: Li, Xiaoye, et al.
Publicado: (2021)

Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study
por: Xie, Yingda L., et al.
Publicado: (2023)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
por: Mueck, Wolfgang, et al.
Publicado: (2013)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_97i3t27m649b6jsgdlh5u22glc